Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. on March 6, 2018, reporting events that occurred on March 1, 2018. The filing addresses changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance matters and contains no financial performance data.
Material Changes
- Resignation of Director: August J. Troendle, M.D., resigned from the Board of Directors effective March 1, 2018. The resignation was not due to any disagreement with the Company, the Board, or management.
- Reclassification of Director: To maintain an equal balance among the three classes of directors as required by the Certificate of Incorporation, V. Bryan Lawlis, Ph.D., resigned from his position as a Class II director and was immediately reappointed as a Class I director.
- Board Size Reduction: Following the reappointment of Dr. Lawlis, the Board decreased the number of authorized directors from eight to seven.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document focuses exclusively on the administrative restructuring of the Board.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors and the specific terms of the remaining directors.
- Verify that the reduction in authorized directors from eight to seven aligns with the Company's long-term governance strategy.
- Review subsequent filings to ensure no undisclosed disagreements existed regarding Dr. Troendle's departure.